Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma

V Mollica, M Rosellini, S Brocchi, F Galuppi… - Expert Review of …, 2024 - Taylor & Francis
Background Radiological response assessment is becoming challenging with novel
immune-based combinations for metastatic renal cell carcinoma (mRCC). RECIST criteria …

Molecular subtypes as potential biomarkers in renal cell carcinoma

CH Chehade, N Agarwal - Cancer Cell, 2024 - Elsevier
The increasing number of approved treatment combinations for metastatic renal cell
carcinoma highlights the need for actionable biomarkers to guide treatment selection. In this …

[HTML][HTML] Tumor microenvironment and clinical efficacy of first line immunotherapy-based combinations in metastatic renal cell carcinoma

E Sammarco, M Rossetti, A Salfi, A Bonato, P Viacava… - Medical Oncology, 2024 - Springer
The impact of tumor microenvironment (TME) in influencing clinical response to first-line
immune checkpoint inhibitor (ICI)-based treatment in advanced renal cell carcinoma (RCC) …

[PDF][PDF] Hope Nyavor. From Bits to Atoms: Machine Learning and Nanotechnology for Cancer Therapy

M Agboklu, FA Adrah… - Journal of Nanotechnology …, 2024 - fortunepublish.com
Cancer therapy has seen significant advancements in recent years, with the integration of
machine learning and nanotechnology emerging as a promising new approach to improve …

and spatial immunogenic traits co-predict the efficacy

L Kinget, AD Garg - nature.com
A machine learning-derived gene signature that integrates germline HLA characteristics with
a distinct spatial community of CD8+ T cells and tumor-associated macrophages showing …